Thyrotoxicosis: Complete Learning Summary

Diagnosis · Disposition · Treatment · Thyroid Function Test (TFT) Pitfalls

Part 1 — Initial Testing & Diagnostic Workup: "TSH First, Then Follow the Arrow"

Day 1 lab panel for suspected thyrotoxicosis TSH (thyroid-stimulating hormone), FT4 (free thyroxine), total T3 (triiodothyronine), TRAb (TSH receptor antibody) or TSI (thyroid-stimulating immunoglobulin), TPO Ab (thyroid peroxidase antibody), CBC w/diff, CMP (including LFTs). Add TgAb (thyroglobulin antibody) if cancer surveillance is relevant. RAIU (radioactive iodine uptake)/scintigraphy is not a first-line test — order only if TRAb is negative or if nodules are palpated.

Step 1 — TSH: the gatekeeper

Low/suppressed → thyrotoxicosis → proceed to Step 2
Normal → hyperthyroidism essentially excluded (rare exception: TSH-oma, a TSH-secreting pituitary adenoma)
High → hypothyroidism

This patient: TSH <0.005 → overt thyrotoxicosis confirmed.

Step 2 — Free Hormones: degree of thyrotoxicosis

FT4 and T3: T3:T4 (thyroxine) ratio >20:1 favors GD (Graves disease)/toxic nodule; <20:1 favors thyroiditis (released stored hormone is predominantly T4).^[2]
Note: total T3 is preferred over FT3 (free triiodothyronine). FT3 represents only ~0.3% of total T3 — the rest is protein-bound — so it must be measured by analog tracer immunoassays that are vulnerable to interference from binding-protein variations, displacing drugs (heparin, NSAIDs, furosemide), heterophilic antibodies, and non-thyroidal illness. Different platforms give different FT3 values for the same sample. Total T3 measures the entire bound + free pool and is more reproducible.^[2][11]

This patient: FT4 3.63 (2.1× ULN (upper limit of normal)) + FT3 11.4 (2.6× ULN) + Total T3 303 (1.7× ULN) → overt hyperthyroidism. T3:T4 ratio >20:1, consistent with GD.

Step 3 — Antibody Testing: "why is this happening?"^[2]

Antibody	Target / meaning	Clinical use
TRAb	Antibody against the TSH receptor — encompasses stimulating, blocking, and neutral forms	Pathognomonic for Graves disease — sensitivity 97.7%, specificity 99.5%. If positive, no imaging needed. Single most useful test in suspected GD.
TSI	Functional subset of TRAb that specifically stimulates the TSH receptor (bioassay)	Correlates with Graves ophthalmopathy (GO) severity. Predicts recurrence risk after ATD (antithyroid drug) course. Useful when TRAb is borderline or when monitoring GO activity.
TPO Ab	Antibody against thyroid peroxidase enzyme	Marker of autoimmune thyroid disease broadly — present in ~75% of GD, ~95% of Hashimoto, and ~10% of the general population. Confirms autoimmunity but not specific to GD.
TgAb	Antibody against thyroglobulin	Another autoimmune marker; less diagnostically useful. Critical post-thyroidectomy for cancer surveillance — interferes with Tg (thyroglobulin) assays and must be measured alongside Tg.

When to order which:

Suspected Graves → TRAb (or TSI) first
TRAb positive → diagnosis established; do not order RAIU
TRAb negative + clear thyrotoxicosis → proceed to Step 4 (imaging) to distinguish toxic nodule vs thyroiditis
TPO Ab / TgAb are supportive, not required for GD diagnosis — but useful for documenting autoimmune background and predicting future hypothyroidism risk

This patient: TRAb 11.60 (6.6× ULN) and TSI 7.83 (14× ULN) → GD confirmed, no imaging needed. TPO Ab 249 and TgAb 13.9 confirm autoimmune thyroid disease but add no diagnostic specificity beyond TRAb. High TSI predicts low remission likelihood after a course of ATD — early discussion of definitive therapy is warranted.

Step 4 — RAIU / Scintigraphy: only if TRAb negative or nodules palpated

Diffuse increased uptake → Graves disease
Focal "hot" uptake → toxic adenoma
Patchy uptake → toxic MNG (multinodular goiter)
Low/absent uptake → thyroiditis (subacute, painless, or exogenous thyroid hormone)

This patient: TRAb/TSI positive → scintigraphy not needed.

Pitfall reminder: high-dose biotin (>100 mg/day, but interference possible at ≥10 mg/day) can cause falsely low TSH and falsely high FT4/T3/TRAb — always ask about supplements if results don't match the clinical picture. See Part 5 for the full TFT interference framework.^[8][2]

Part 2 — Inpatient vs. Outpatient Is a Clinical Decision, Not a Lab Decision

Thyroid hormone levels in thyroid storm are indistinguishable from those in compensated thyrotoxicosis.^[1][2] The Burch-Wartofsky Point Scale (BWPS) — the standard scoring system for thyroid storm — is based entirely on clinical parameters with zero laboratory criteria.^[3]

This patient: FT4 3.63 (>2× ULN) and FT3 11.4 (>2.5× ULN) — markedly elevated. But if the patient is sitting in clinic with HR 95, no fever, no AMS, no GI symptoms, and no CHF → outpatient management. The same labs in a patient with HR 140, temp 103°F, agitation, and vomiting → ICU admission for thyroid storm.

BWPS Categories

(≥45 = thyroid storm; 25–44 = impending storm; <25 unlikely)^[3]

Category	Gradations
Temperature	°F (graded bands from 99 to ≥104)
CNS effects	absent → mild agitation → moderate (delirium, psychosis, extreme lethargy) → severe (seizure, coma)
GI-hepatic dysfunction	absent → moderate (diarrhea, N/V, abdominal pain) → severe (unexplained jaundice)
Heart rate	bpm (graded bands from 99 to ≥140)
CHF	absent → mild (pedal edema) → moderate (bibasilar rales) → severe (pulmonary edema)
Atrial fibrillation	present or absent
Precipitating event	present or absent

Indications for Inpatient Management (clinical, not lab-based)^[3][4]

BWPS ≥45 (thyroid storm) or 25–44 (impending — use clinical judgment)
Hemodynamic instability (tachycardia refractory to β-blockade, hypotension)
Fever/hyperpyrexia
AMS (agitation, delirium, psychosis, obtundation)
New-onset AF with RVR
Acute CHF or high-output cardiac failure
Severe GI symptoms (intractable vomiting, diarrhea, hepatic failure)
Identified precipitant requiring inpatient management (sepsis, surgery, DKA)

Part 3 — Treatment Algorithm: Block, Brake, Boost, Bind, Break

5 B's Block (β-blocker) · Brake (ATD) · Boost (steroids) · Bind (iodine/cholestyramine) · Break (RAI (radioactive iodine)/thyroidectomy)

Block and Brake are used in every case. Boost and Bind are add-ons for severe/refractory disease. Break is definitive therapy.^[1][2]

Pathway A — Outpatient (Compensated Thyrotoxicosis)

Step 1: BLOCK — β-Blocker

Symptom control. Propranolol at doses ≥160 mg/day additionally inhibits peripheral T4-to-T3 conversion by 20–30%.^[2][3]

Agent	Dose	Frequency	Key features
Propranolol (preferred)	10–40 mg start; up to 320 mg/day	TID–QID	Nonselective; blocks T4→T3 at high doses
Propranolol LA	60–160 mg	Once daily	Better adherence; same drug
Atenolol	25–100 mg	QD–BID	β1-selective; avoid in pregnancy
Metoprolol	25–50 mg	BID–TID	β1-selective; widely available
Nadolol	40–160 mg	Once daily	Nonselective; may block T4→T3

When β-blockers contraindicated (asthma, decompensated CHF, bradyarrhythmia, Raynaud) → non-DHP CCB (non-dihydropyridine calcium channel blocker):^[3][5]

Diltiazem generally preferred — IV and PO available, titratable, less negative inotropy than verapamil
Verapamil equally effective for rate control but stronger negative inotropy — avoid in HFrEF (heart failure with reduced ejection fraction)
Both contraindicated in WPW (Wolff-Parkinson-White) pre-excitation
Outpatient: diltiazem ER (extended-release) 120–360 mg/day; verapamil ER 120–480 mg/day

Step 2: BRAKE — Antithyroid Drug (ATD)

Methimazole (MMI) is first-line over propylthiouracil (PTU) for three reasons:^[2][6]

Better efficacy — faster normalization of FT4, FT3, TSH in RCT meta-analysis
Once-daily dosing — MMI t½ (half-life) ~6 hr vs PTU ~1.5 hr
Safer liver profile — PTU carries FDA boxed warning for fulminant hepatic necrosis (~2.7%); MMI hepatotoxicity is typically cholestatic and reversible (~0.4%)

When to use PTU instead: first trimester of pregnancy (MMI embryopathy: aplasia cutis, choanal/esophageal atresia); thyroid storm (PTU additionally blocks T4→T3 conversion, though recent comparative effectiveness data show no mortality difference); MMI allergy/intolerance.^[2]

MMI Starting Dose by FT4 Severity

This patient: FT4 3.63 / ULN 1.77 = 2.1× ULN → start MMI 30–40 mg/day.

FT4 level	MMI starting dose	This patient?
1.0–1.5× ULN	5–10 mg/day	—
1.5–2.0× ULN	10–20 mg/day	—
2.0–3.0× ULN	30–40 mg/day	✓ FT4 3.63 = 2.1× ULN
>3.0× ULN (severe)	40–60 mg/day	consider inpatient

Before starting any ATD: baseline CBC w/diff and LFTs — not to preclude treatment, but as a reference for later agranulocytosis (0.2–0.5% risk, highest in first 90 days) or hepatotoxicity questions.^[2][6]

This patient: 4/20 labs show AST 229 / ALT 184 — thyrotoxic hepatitis, not baseline liver disease. By 5/11 they normalized (AST 21, ALT 33). The 5/11 values serve as true pre-ATD baseline. ANC 3.0 on 5/11 is a good baseline — if it drops below 1.0 on ATD, that is concerning; below 0.5 = agranulocytosis → stop drug immediately.

Titration Method (Maintenance Dosing)

The standard approach is the titration method — preferred over "block-and-replace" because the latter requires higher ATD doses with more side effects and no proven benefit.^[1][4]

Start MMI 20 mg BID (40 mg/day) given the severity
At 4–6 weeks, if FT4 trending toward normal → reduce to 20 mg once daily
At 8–12 weeks, if FT4 and T3 normalizing and TSH recovering → reduce to 10 mg/day
Goal: maintenance dose of 5–10 mg/day by ~6 months^[2][3]
If FT4/T3 not improving at 4–6 weeks, ensure adherence before increasing dose — non-adherence is the most common cause of treatment failure^[2]

Patient Counseling — When to Stop MMI and Call Immediately

A survey found that 61% of patients on ATDs were unfamiliar with the symptoms of agranulocytosis.^[2] Communicate clearly — ideally both verbally and in writing.

STOP MMI immediately and go to the ER / call the office if any of the following occur^[1][2][5]

"FAST" mnemonic for patients:

F — Fever (especially >101°F / 38.3°C with no obvious cause)
A — Aching throat (severe sore throat, difficulty swallowing — the hallmark of agranulocytosis)
S — Skin turning yellow (jaundice — hepatotoxicity) or dark urine (tea/cola-colored)
T — Terrible rash (widespread, blistering, or not responding to antihistamines)

What Happens at the ER

STAT CBC with differential and LFTs.^[1][2]

Finding	Action
ANC <0.5 × 10⁹/L = agranulocytosis	Stop MMI permanently; admit; broad-spectrum antibiotics; G-CSF (granulocyte colony-stimulating factor)
ANC <1.0 but >0.5	Concerning — hold drug, recheck in 24–48 hours
LFTs: hepatocellular injury (AST/ALT >3× ULN or rising bilirubin)	Stop MMI; do not rechallenge

Timing of highest risk The first 90 days after starting MMI carry the highest risk for both agranulocytosis and hepatotoxicity. After 90 days, risk drops substantially but does not reach zero — agranulocytosis can occur on re-exposure even after years.^[1][2]

Additional Counseling Points

Minor rash/itching (~6%) can often be managed with antihistamines without stopping MMI — but if it worsens or becomes widespread, stop and call^[1][2]
Do not stop MMI on your own for any other reason without calling — abrupt discontinuation can cause rebound thyrotoxicosis
If pregnancy is planned, notify the physician immediately — MMI must be switched to PTU in the first trimester due to embryopathy risk, then switched back to MMI after week 16

Duration: treat 12–18 months, then check TRAb — if normalized, trial off. Remission rate ~40–50%. Long-term low-dose MMI is safe if remission not achieved.^[2]

This patient: TRAb 11.60 (>6× ULN) before starting ATD is an independent predictor of recurrence — remission likelihood is low. Early discussion of definitive therapy is warranted.^[2]

Optional Outpatient Add-on — BIND (cholestyramine)

For patients needing faster hormone reduction: cholestyramine 4 g PO BID–QID (even 1–2 g BID effective) binds T4/T3 in the gut, interrupting enterohepatic recirculation. At 4 weeks, significant additional FT4 reduction (mean diff −1.0 ng/dL) vs standard therapy alone.^[7]

Pathway B — Inpatient (Thyroid Storm / Severe Thyrotoxicosis)

All steps initiated simultaneously, with one critical timing exception noted.^[3][4]

Step 1: BLOCK — IV β-Blocker

Esmolol IV drip 50–100 μg/kg/min — preferred when hemodynamic instability requires minute-to-minute titration (ultra-short t½ ~9 min)
Propranolol 60–80 mg PO q4h (or 1 mg IV slow push, repeat q10–15 min)
If β-blockers contraindicated → diltiazem IV bolus 0.25 mg/kg over 2 min, then drip 5–15 mg/hr

Avoid aspirin/salicylates for fever — they displace T4 from TBG (thyroxine-binding globulin), increasing free T4. Use acetaminophen + cooling blankets.^[3][4]

Step 2: BRAKE — High-dose ATD

PTU (preferred in storm): 500–1000 mg PO/NG load → 250 mg q4h
Alternative: MMI 60–80 mg/day PO/NG
Both can be given rectally if PO/NG not possible

Step 3: BIND (iodine) — SSKI (saturated solution of potassium iodide)

⚠️ Must wait ≥1 hour after the first ATD dose. Giving iodine before ATD provides substrate for new hormone synthesis (escape from Wolff-Chaikoff effect).^[3]

SSKI 5 drops (~250 mg) PO q6h
Alternative: Lugol solution 10 drops TID

Step 4: BOOST — Glucocorticoids

Dexamethasone 2 mg IV/PO q6h (no mineralocorticoid effect) — preferred when the goal is to maximally block T4→T3 conversion
Hydrocortisone 300 mg IV load → 100 mg IV q8h — preferred when adrenal insufficiency prophylaxis is the primary concern
Mechanism: blocks peripheral T4→T3 conversion (↓ type 1 5'-deiodinase, possibly ↑ type 3 deiodinase, shifting T4 metabolism toward rT3 (reverse T3) rather than active T3) + prophylaxis against relative adrenal insufficiency + anti-inflammatory^[8][22]
Taper once storm resolves (see schedule below)

Glucocorticoid Choice for T4→T3 Blockade

Dexamethasone has the best-documented and most potent inhibition of peripheral T4-to-T3 conversion among glucocorticoids. Dexamethasone 8 mg/day reduces serum T3 by 37–50% in Graves disease, with T3 beginning to fall at 24 hours and remaining suppressed for ≥5 days.^[22] This effect is explicitly "exploited therapeutically" in severe thyrotoxicosis.^[8]

Steroid	T4→T3 blockade	Dose studied	T3 reduction
Dexamethasone	Strong, well-documented	2 mg q6h (8 mg/day)	30–50%
Hydrocortisone	Probable, less well-characterized — ATA says it "may" block T4→T3	300 mg load → 100 mg q8h	Not well quantified
Prednisone	Minimal at standard doses	20 mg/day	No significant change

FDA levothyroxine labeling cites glucocorticoids ≥dexamethasone 4 mg/day as the threshold for the ~30% T3 reduction class effect. Methylprednisolone and betamethasone aren't specifically studied for this indication, but high-potency synthetic glucocorticoids at supraphysiologic doses are expected to share the effect — higher potency and higher dose correlate with greater inhibition of peripheral deiodination.^[21]

Bottom line For T4→T3 blockade specifically: dexamethasone 2 mg IV/PO q6h. For adrenal insufficiency prophylaxis as the primary concern: hydrocortisone. Prednisone at standard doses doesn't reliably reduce T3 — don't substitute it for either.

Practical Dexamethasone Algorithm

There is no published, standardized dexamethasone taper protocol for thyroid storm in any guideline — ATA and expert reviews simply say "taper and discontinue once clinical improvement occurs."^[3][21] A reasonable decision-tree:

Timepoint	State	Action
Day 0	Initial storm management	Dexamethasone 2 mg IV q6h + PTU + propranolol + SSKI (≥1 hr after PTU)
Day 2–3	Improving (↓HR, ↓temp, AMS clearing)	Begin taper: 2 mg q12h × 1 d → 2 mg daily × 1 d → stop
Day 2–3	NOT improving	Continue full dose; consider TPE or emergency thyroidectomy

Typical total course ≤ 5 days. Taper is based on clinical improvement, not a specific FT4 or TSH cutoff. Dexamethasone serves two time-limited purposes (T4→T3 blockade + coverage for relative adrenal insufficiency); prolonged courses don't add benefit and carry the usual steroid risks.

Why a short course is safe

The T4→T3 blockade outlasts the dosing period — Chopra et al. showed T3 suppression persisted ≥5 days after a single 24-hour course^[22]
If course is ≤3 days → can stop abruptly per the Endocrine Society/ESE 2024 guideline on glucocorticoid-induced adrenal insufficiency, since clinically significant adrenal suppression is unlikely after short-term high-dose use^[23]
Hyperthyroid patients have increased metabolic clearance of corticosteroids, which may further reduce the risk of prolonged HPA (hypothalamic-pituitary-adrenal) axis suppression in this population
If course extends >5–7 days (refractory storm), switch to a shorter-acting glucocorticoid (hydrocortisone or prednisone) to facilitate HPA recovery — dexamethasone's long half-life makes HPA recovery harder^[23]

Preoperative preparation for emergency thyroidectomy: dexamethasone should be tapered within the first 72 hours after surgery.^[21] Panzer et al. used a lower-dose regimen (dexamethasone 1 mg BID) in combination with iopanoic acid and thionamides for rapid preoperative preparation, continuing until patients were clinically euthyroid — typically days to a couple of weeks.^[24]

Step 5: BIND — Cholestyramine

4 g PO/NG QID — binds T4/T3 in gut, interrupting enterohepatic recirculation^[2][7]

Step 6: RESCUE — If refractory

TPE (therapeutic plasma exchange) — rapidly reduces circulating T4/T3; bridge to emergency thyroidectomy
Emergency thyroidectomy — when medical therapy fails

Supportive: cooling blankets (not aspirin), volume resuscitation, antibiotics if infection is precipitant, nutritional support, ICU monitoring.^[3][4]

Lab Monitoring in the ICU

Marker	Use in the ICU
Free T4	Primary trending marker. Most reliable in the ICU; less affected by binding-protein changes than total T3.
Free T3	Reasonable secondary marker despite assay imprecision (see below).
Total T3	Do NOT rely on this in the ICU. Confounded by low binding proteins (TBG, albumin) and NTIS (non-thyroidal illness syndrome). Can read paradoxically low despite active thyrotoxicosis.
TSH	Useless acutely — stays suppressed for weeks to months after thyrotoxicosis resolves.

Why total T3 is misleading in the ICU Total T3 = protein-bound + free T3 (~99.7% bound). In the ICU, TBG and albumin drop (inflammation, malnutrition, hepatic dysfunction, capillary leak) → disproportionate fall in total T3 even when the thyroid is overproducing. NTIS layers on top: ↓D1 deiodinase + ↑D3 deiodinase activity → less T3 production from T4. Total T3 can read low while the patient is actively thyrotoxic.

Illustrative ICU snapshot: total T3 70.7 ng/dL (low/normal) with FT3 4.82 pg/mL (elevated) and FT4 3.92 ng/dL (markedly elevated). The free fractions tell the real story; the total T3 has been "consumed" by binding-protein loss. Trust the free fractions; ignore the total.

Why free T3 is imperfect but better than total T3 in the ICU ATA recommends total T3 over FT3 for general practice because of FT3's assay imprecision. The opposite is true in the ICU: binding-protein confounding of total T3 is a bigger problem than FT3 assay imprecision. FFAs, heparin, and ICU drugs can artifactually elevate FT3 on immunoassay, but in discordant cases FT3 still better reflects clinical features and TSH/FT4 than total T3 (Castilho et al. 2026). Bottom line: in ICU thyrotoxicosis, FT3 > total T3 for monitoring, but FT4 remains the primary trending lab.

FT4 Goals

Dexamethasone taper / general storm management: no guideline-defined FT4 target — taper is clinical (see algorithm above)
Pre-thyroidectomy in refractory storm: FT4 goal ~2.5–3.3 ng/dL (Calderon et al. 2026 TPE case series)
Outpatient ATD titration: FT4 into normal range (~0.6–1.6 ng/dL)

Pathway C — Preoperative Preparation (Elective Thyroidectomy)^[2]

Render euthyroid with MMI (1–3 months)
Add SSKI 2–3 drops PO TID for 7–10 days preop (reduces thyroid vascularity)
Continue β-blocker perioperatively
If cannot render euthyroid (ATD allergy, urgent): β-blocker + SSKI + dex 2 mg QID + cholestyramine 4 g QID

Definitive Therapy — BREAK^[2][3]

Both RAI and total thyroidectomy are equally effective at curing Graves disease (definitive cure >90%). The choice is driven by patient anatomy, comorbidities, GO status, pregnancy plans, and patient preference. Both render the patient hypothyroid (intentional in GD) and both require lifelong levothyroxine.

Choosing Between RAI and Thyroidectomy — Stable / Outpatient Patient

Factor	Favors RAI	Favors thyroidectomy
Goiter size	Small to moderate (<80 g)	Large (≥80 g) — RAI less effective; compressive symptoms (dyspnea, dysphagia, stridor)
Nodules	None suspicious	Suspicious nodule on US/FNA requiring histology
Graves ophthalmopathy	None or mild/inactive	Moderate-severe active GO, especially in smokers (RAI can worsen GO)
TRAb level	Low to moderate	Very high TRAb — predicts RAI failure
Pregnancy plans	Not planning within 6–12 months	Pregnancy planned <6–12 months; pregnant in 2nd-3rd trimester
Coexisting hyperparathyroidism	—	Combined parathyroidectomy + thyroidectomy in one operation
Surgical / anesthesia risk	High cardiopulmonary risk	Acceptable surgical risk
Access to surgeon	No experienced thyroid surgeon available	High-volume thyroid surgeon available — complication rates depend heavily on surgeon volume
Speed of resolution	OK with weeks-to-months	Need rapid, immediate control
Patient preference	Avoid surgery / scar	Avoid radiation exposure; want definitive same-day control
Cost / logistics	Lower cost; outpatient single visit	Higher cost; OR + inpatient stay

Complications

Approach	Risks
RAI	Permanent hypothyroidism (expected, requires lifelong levothyroxine); worsening of active GO (use prednisone prophylaxis if active GO, especially in smokers); transient radiation thyroiditis with worsening thyrotoxicosis (1–3%); rare salivary gland damage; pregnancy/breastfeeding contraindicated 6–12 months
Total thyroidectomy	Transient hypoparathyroidism (~10–20%); permanent hypoparathyroidism (1–4%); RLN injury (1–4%); permanent hypothyroidism (100%); general surgical/anesthesia risks; complication rates strongly dependent on surgeon volume

ICU / Thyroid Storm Setting

⚠️ RAI is contraindicated in acute thyroid storm or in the critically ill hospitalized patient. RAI can precipitate storm via transient radiation thyroiditis. Reasons against acute use: (1) takes weeks-to-months to work — useless for acute crisis; (2) the radiation thyroiditis release can worsen — or precipitate — storm; (3) patient should be euthyroid before treatment for safety.

In the ICU/storm setting, the only definitive option is emergency total thyroidectomy, reserved for:

Medical therapy failure in thyroid storm (refractory to ATD + iodine + β-blocker + steroids + cholestyramine)
ATD intolerance or contraindication (severe allergy, agranulocytosis, fulminant hepatitis on PTU or MMI)
Life-threatening thyrotoxicosis that cannot be controlled medically

Bridge to OR: β-blocker + iodine (SSKI) + dexamethasone + cholestyramine ± TPE. The Panzer protocol (iopanoic acid + dexamethasone + thionamide) is used at experienced centers for rapid preoperative preparation.^[24] Emergency thyroidectomy in the storm setting historically carried 10–30% mortality but is substantially lower at high-volume centers with multidisciplinary preparation.^[4]

Definitive therapy after recovery: plan RAI or thyroidectomy as an outpatient once the patient is euthyroid on ATDs and the iodine load has washed out — typically 2–6 weeks after stopping SSKI, since residual iodine reduces RAI uptake and effectiveness.

Part 4 — Drug Side Effects

Drug	Common	Serious / rare	Monitoring
MMI	Rash/urticaria (6%), arthralgias (1–5%), GI upset, taste/smell changes	Agranulocytosis (0.2–0.5%, highest first 90 days); cholestatic hepatitis (0.4%); pancreatitis; embryopathy (1st trimester)	Baseline CBC + LFTs; symptom-based (fever/sore throat → STAT CBC)
PTU	Rash/urticaria (3%), arthralgias, GI upset	⚠️ FDA boxed warning: fulminant hepatic necrosis (2.7%); agranulocytosis (0.2–0.5%); ANCA (anti-neutrophil cytoplasmic antibody)-positive vasculitis (up to 3%, increases with duration)	Baseline CBC + LFTs; symptom-based
Propranolol	Fatigue, cold extremities, bradycardia, dizziness, GI upset	Bronchospasm, severe bradycardia, hypotension, masking of hypoglycemia, depression	HR/BP; glucose in diabetics
Esmolol (IV)	Hypotension (dose-dependent), injection site reactions	Severe bradycardia, bronchospasm	Continuous HR/BP (ICU)
Diltiazem	Bradycardia, hypotension, peripheral edema, constipation, dizziness	AV block, severe hypotension (esp. with β-blocker combo), worsening CHF	HR, BP, ECG
Verapamil	Same as diltiazem + more constipation	Stronger negative inotropy — avoid in HFrEF; AV block	HR, BP, ECG, LV function
SSKI / KI (potassium iodide)	Metallic taste, nausea, sialadenitis, acneiform rash	Iodine hypersensitivity (rare); escape from Wolff-Chaikoff after 1–2 wk; ⚠️ give ≥1 hr after ATD	TFTs; limit to 7–14 days in storm
Hydrocortisone	Hyperglycemia, fluid retention, insomnia, GI upset	Adrenal suppression (prolonged), infection risk, GI bleed, psychosis (high dose)	Glucose; taper when storm resolves
Dexamethasone	Hyperglycemia, insomnia, mood changes	Same as HCT (hydrocortisone) but no mineralocorticoid effect (less fluid); adrenal suppression	Glucose
Cholestyramine	Constipation (most common), bloating, abdominal discomfort, nausea	Impaired absorption of other drugs (separate by 1 hr before / 4 hr after); fat-soluble vitamin malabsorption (A, D, E, K) with prolonged use	Timing of other meds; stool frequency
RAI	Transient neck pain/swelling, radiation thyroiditis (1–3%), transient worsening of thyrotoxicosis	Permanent hypothyroidism (expected in GD); worsening of GO — steroid prophylaxis if active GO; rare salivary damage	TFTs q4–6 wk post-RAI; lifelong levothyroxine

This patient — monitoring plan: baseline ANC 3.0 (5/11) and ALT 33 / AST 21 (5/11, post-resolution of thyrotoxic hepatitis). If started on MMI 30 mg/day: (1) any fever/sore throat → STAT CBC r/o agranulocytosis; (2) jaundice/dark urine → STAT LFTs; (3) glucose 122 and A1c 5.7 should be rechecked after euthyroidism to determine if truly prediabetic or thyrotoxic hyperglycemia.

Part 5 — Drugs and Supplements That Interfere with TFTs

Critical section — these substances cause spurious TFT results in euthyroid patients, leading to misdiagnosis and inappropriate treatment. Over 50% of documented thyroid assay interferences have led to misdiagnosis and/or inappropriate management.^[9]

Category A — Assay Interference (patient is euthyroid; labs are wrong)^[8]

Substance	TSH	FT4	T3	Condition mimicked	Mechanism / what to do
Biotin (vit B7)	↓ falsely low	↑ falsely high	↑ falsely high	Primary hyperthyroidism (can cause false-positive TRAb)	Competes with biotinylated reagents in streptavidin-biotin immunoassays. Stop ≥2–7 days before retest; interference possible at doses as low as 10 mg/day
Heparin / enoxaparin	Normal	↑ falsely high	↑ falsely high	TSH-oma, thyroid hormone resistance	Generates FFAs (free fatty acids) in vitro that displace T4 from binding proteins. Draw blood before heparin dose; analyze immediately
Heterophilic antibodies (e.g., HAMA, human anti-mouse antibodies)	↑ or ↓	Variable	Variable	Various	Cross-react with assay antibodies. Method comparison on different platform; heterophilic blocking reagents
Macro-TSH	↑ falsely high	Normal	Normal	Subclinical hypothyroidism (~1% of cases)	TSH bound to immunoglobulins; cleared slowly. PEG (polyethylene glycol) precipitation; gel filtration

Biotin deserves special emphasis. OTC (over-the-counter) supplements marketed for hair/nails typically contain 5–10 mg (167–333× the RDI (recommended daily intake) of 30 μg). High-dose biotin (300 mg/day) used for MS (multiple sclerosis) causes dramatic interference. The pattern — low TSH, high FT4, high T3, and even false-positive TRAb — perfectly mimics Graves disease and has led to unnecessary ATD treatment and RAI.^[8][14][15]

This patient: always ask about biotin and other supplements before interpreting TFTs. Here the clinical picture (tachycardia, tremor, weight loss) matched the labs, and TRAb/TSI were markedly positive — making biotin interference extremely unlikely. But if a patient has "Graves labs" with no symptoms, biotin interference should be the first consideration.

Category B — Drugs That Cause TRUE Thyroid Dysfunction (labs are correct)^{[2][8][12][17]}

Drug	Thyroid effect	Mechanism	Monitoring
Amiodarone	Hypothyroidism (13–17%) or thyrotoxicosis (AIT (amiodarone-induced thyrotoxicosis), 9%); 5-yr cumulative ~40%	AIT type 1: iodine excess → ↑ synthesis (pre-existing goiter); AIT type 2: destructive thyroiditis; hypothyroidism: direct toxicity + Wolff-Chaikoff	TSH q3–6 mo on therapy, then q6 mo; continue 6–12 mo after stopping (t½ ~100 d)
Lithium	Hypothyroidism (5–15%); goiter; rarely hyperthyroidism	Inhibits iodine uptake, hormone synthesis, and release; ↑ thyroid autoimmunity	TSH baseline, q6–12 mo
ICIs (immune checkpoint inhibitors) (anti-PD-1 (programmed cell death protein-1), anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein-4))	Thyrotoxicosis (transient, destructive) → often evolves to hypothyroidism (50–90%); most common endocrine irAE (immune-related adverse event)	Cytotoxic T-cell-mediated thyroid destruction; ATDs NOT indicated (destructive, not synthetic)	TSH + FT4 q4–6 wk during therapy
TKIs (tyrosine kinase inhibitors) (sunitinib, sorafenib)	Hypothyroidism (up to 27%)	Destructive thyroiditis; impaired iodine uptake; capillary regression	TSH q4–8 wk
Interferon-α	Hypo- or hyperthyroidism; autoimmune thyroiditis	Autoimmune	TSH q3 mo during therapy
Alemtuzumab	Graves disease in up to 30–40%	Immune reconstitution → autoimmune GD	TSH q3 mo for 4 yr after last dose

Category C — Altered Binding, Metabolism, or Absorption (labs change; clinical significance varies)

Drug / class	Effect on TFTs	Mechanism	Clinical significance
Oral estrogen (OCP (oral contraceptive pill), HRT (hormone replacement therapy))	↑ Total T4/T3 (FT4 usually normal)	↑ TBG production (hepatic first-pass)	Patients on levothyroxine may need dose increase; transdermal estrogen has minimal effect
Androgens, glucocorticoids, niacin	↓ Total T4/T3 (FT4 usually normal)	↓ TBG production	Rarely clinically significant; glucocorticoids also suppress TSH centrally
Phenytoin, carbamazepine	↓ FT4 (assay artifact); normal TSH	Displace T4 from binding proteins + enhance T4 metabolism via CYP (cytochrome P450) induction	Artifactually low FT4 mimics central hypothyroidism — patient is euthyroid; levothyroxine dose may need increase
Salsalate	↓ FT4; normal TSH	Displaces T4 from binding proteins	Same artifact as phenytoin — patient is euthyroid
Cholestyramine, colestipol	↓ T4/T3 levels	Binds thyroid hormone in gut; impairs levothyroxine absorption	Separate levothyroxine dosing by ≥4 hours
Metformin	↓ TSH in hypothyroid patients	Unclear; may enhance TSH suppression	May cause apparent "improvement" in subclinical hypothyroidism — not a true thyroid effect
Glucocorticoids (high dose)	↓ TSH; ↓ T3	Central TSH suppression + inhibit T4→T3 conversion	Can mimic central hypothyroidism or mask thyrotoxicosis; dose-dependent and reversible

Quick rule of thumb If the clinical picture does not match the labs → suspect assay interference or drug effect. Most common culprits to ask about: biotin supplements, heparin (recent administration), amiodarone, lithium, ICIs, estrogen, antiepileptics.^[8][9][12]

Part 6 — Case Comments

Confirmed Graves disease — TRAb 11.60 and TSI 7.83 are both markedly elevated, confirming the diagnosis without need for imaging.^[2]

Thyrotoxic hepatitis — AST 229 → 21 and ALT 184 → 33 normalization without liver-directed therapy is classic. The hepatocellular pattern (AST/ALT predominant) is the typical thyrotoxic pattern, distinct from the cholestatic pattern of MMI-induced hepatotoxicity. This means the 5/11 labs (post-resolution) — not the 4/20 labs — serve as the true pre-ATD baseline.

Abbreviations

Thyroid- and specialty-specific terms only. Universal medical abbreviations (TSH, FT4, BID, IV, ICU, HR, BP, ECG, AST, ALT, CBC, etc.) are not listed.

Abbreviation	Expansion	Abbreviation	Expansion
AIT	Amiodarone-induced thyrotoxicosis	NTIS	Non-thyroidal illness syndrome
ANCA	Anti-neutrophil cytoplasmic antibody	OCP	Oral contraceptive pill
ATD	Antithyroid drug	PD-1	Programmed cell death protein-1
BWPS	Burch-Wartofsky Point Scale	PEG	Polyethylene glycol
CCB	Calcium channel blocker	PTU	Propylthiouracil
CTLA-4	Cytotoxic T-lymphocyte-associated protein-4	RAI	Radioactive iodine
CYP	Cytochrome P450	RAIU	Radioactive iodine uptake
DHP	Dihydropyridine	RDI	Recommended daily intake
FFA	Free fatty acid	RLN	Recurrent laryngeal nerve
G-CSF	Granulocyte colony-stimulating factor	rT3	Reverse triiodothyronine
GD	Graves disease	SSKI	Saturated solution of potassium iodide
GO	Graves ophthalmopathy	TBG	Thyroxine-binding globulin
HAMA	Human anti-mouse antibodies	TFT	Thyroid function test
HCT	Hydrocortisone	Tg	Thyroglobulin
HFrEF	Heart failure with reduced ejection fraction	TgAb	Thyroglobulin antibody
HPA	Hypothalamic-pituitary-adrenal (axis)	TKI	Tyrosine kinase inhibitor
HRT	Hormone replacement therapy	TPE	Therapeutic plasma exchange
ICI	Immune checkpoint inhibitor	TPO Ab	Thyroid peroxidase antibody
irAE	Immune-related adverse event	TRAb	TSH receptor antibody
KI	Potassium iodide	TSH-oma	TSH-secreting pituitary adenoma
LA	Long-acting	TSI	Thyroid-stimulating immunoglobulin
MMI	Methimazole	ULN	Upper limit of normal
MNG	Multinodular goiter	WPW	Wolff-Parkinson-White
MS	Multiple sclerosis	t½	Half-life

References

Wiersinga WM, Poppe KG, Effraimidis G. Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis. Lancet Diabetes Endocrinol. 2023;11(4):282–298.
Lee SY, Pearce EN. Hyperthyroidism: a review. JAMA. 2023;330(15):1472–1483.
Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343–1421.
Kopp PA, Giordani I, Feldt-Rasmussen U, Forget-Renaud A. Approach to the patient with thyroid storm. J Clin Endocrinol Metab. 2026;111(5):1484–1494.
Joglar JA, Chung MK, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation. J Am Coll Cardiol. 2024;83(1):109–279.
De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet. 2016;388(10047):906–918.
Moreno Watashi D, Sehgal A, Tejada Frisancho F, et al. Efficacy and safety of adjunctive bile acid sequestrant therapy for thyrotoxicosis: a systematic review and meta-analysis of RCTs. Thyroid. 2026;36(1):17–24.
Burch HB. Drug effects on the thyroid. N Engl J Med. 2019;381(8):749–761.
Favresse J, Burlacu MC, Maiter D, Gruson D. Interferences with thyroid function immunoassays: clinical implications and detection algorithm. Endocr Rev. 2018;39(5):830–850.
Ylli D, Soldin SJ, Stolze B, et al. Biotin interference in assays for thyroid hormones, thyrotropin and thyroglobulin. Thyroid. 2021;31(8):1160–1170.
Van Uytfanghe K, Ehrenkranz J, Halsall D, et al. TSH and thyroid hormones (T3 and T4): an ATA-commissioned review of current clinical and laboratory status. Thyroid. 2023;33(9):1013–1028.
Al-Bahadili H, Powers Carson J, Markov A, Jasim S. The complex web of interferences with thyroid function tests. Endocr Pract. 2025;31(1):92–101.
Taylor PN, Medici MM, Hubalewska-Dydejczyk A, Boelaert K. Hypothyroidism. Lancet. 2024;404(10460):1347–1364.
Elston MS, Sehgal S, Du Toit S, Yarndley T, Conaglen JV. Factitious Graves disease due to biotin immunoassay interference — a case and review of the literature. J Clin Endocrinol Metab. 2016;101(9):3251–3255.
Charles S, Agrawal N, Blum M. Erroneous thyroid diagnosis due to over-the-counter biotin. Nutrition. 2019;57:257–258.
Li D, Radulescu A, Shrestha RT, et al. Association of biotin ingestion with performance of hormone and nonhormone assays in healthy adults. JAMA. 2017;318(12):1150–1160.
Martinez Quintero B, Yazbeck C, Sweeney LB. Thyroiditis: evaluation and treatment. Am Fam Physician. 2021;104(6):609–617.
Guðjónsson P, Jóhannesson AJ, Eyþórsson E, Andersen K. Amiodarone-induced thyroid dysfunction: a high cumulative incidence in a nationwide cohort study in Iceland. J Intern Med. 2025.
National Comprehensive Cancer Network. Management of immune checkpoint inhibitor-related toxicities. Updated 2025-10-23.
Kalra S, Aggarwal S, Khandelwal D. Thyroid dysfunction and dysmetabolic syndrome: the need for enhanced thyrovigilance strategies. Int J Endocrinol. 2021;2021:9641846.
Suwansaksri N, Preechasuk L, Kunavisarut T. Nonthionamide drugs for the treatment of hyperthyroidism: from present to future. Int J Endocrinol. 2018;2018:5794054.
Chopra IJ, Williams DE, Orgiazzi J, Solomon DH. Opposite effects of dexamethasone on serum concentrations of 3,3',5'-triiodothyronine (reverse T3) and 3,3',5-triiodothyronine (T3). J Clin Endocrinol Metab. 1975;41(5):911–920.
Beuschlein F, Else T, Bancos I, et al. European Society of Endocrinology and Endocrine Society joint clinical guideline: diagnosis and therapy of glucocorticoid-induced adrenal insufficiency. J Clin Endocrinol Metab. 2024;109(7):1657–1683.
Panzer C, Beazley R, Braverman L. Rapid preoperative preparation for severe hyperthyroid Graves disease. J Clin Endocrinol Metab. 2004;89(5):2142–2144.

← Back to All Posts

THyrotoxicosis